Orphan Europe Overview

  • Founded
  • 1990
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 73
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Orphan Europe General Information

Description

Developer of orphan medicinal products. The company's orphan medicinal products include Cystadane, Cystagon, Normosang and Wilzin for metabolic disorders, enabling patients to access a wide range of products for their treatment under one roof.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 70, avenue du Général de Gaulle
  • 92800 Puteaux
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orphan Europe Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Orphan Europe‘s full profile, request access.

Request a free trial

Orphan Europe Executive Team (1)

Name Title Board Seat Contact Info
Eric Pottier Chief Pharmaceutical Officer
To view Orphan Europe’s complete executive team members history, request access »

Orphan Europe Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial